propranolol + novel endocrine therapy + androgen deprivation therapy

Propranolol + novel endocrine therapy + androgen deprivation therapy is a combination regimen being investigated for the neoadjuvant treatment of high-risk prostate cancer. This therapeutic approach combines propranolol, a non-selective beta-adrenergic receptor blocker, with standard-of-care androgen deprivation therapy (ADT) and novel endocrine therapies (NET), such as second-generation androgen receptor signaling inhibitors (e.g., abiraterone or enzalutamide). The rationale for adding propranolol is based on evidence that beta-adrenergic signaling, driven by stress hormones, can promote tumor growth, angiogenesis, and resistance to therapy in prostate cancer. By inhibiting these pathways, the regimen aims to enhance the efficacy of hormonal blockade, potentially improving pathological outcomes and long-term survival for patients undergoing radical prostatectomy.

Other names

propranolol + novel endocrine therapy + androgen deprivation therapy-Zhongda Hospital-prostate cancerPropranolol combined with novel endocrine therapy and androgen deprivation therapy